Olfi

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Olfi

Quick Facts

Property Description
Active ingredient Ofloxacin (INN)
Form Tablet (oral), Solution (ophthalmic, otic)
Pharmacological class Fluoroquinolone Antibiotic
Common use Treatment of bacterial infections
Origin Synthetic

What Type of Medicine is Olfi?

Olfi is a synthetic broad-spectrum antibiotic whose activity is derived from the active ingredient, Ofloxacin. This compound is rigorously classified within the fluoroquinolone antibiotic family, representing a type of anti-infective agent that is chemically synthesized. Ofloxacin is specifically recognized as a second-generation agent within the broader quinolone antibiotics group, having been clinically recognized for its systemic antibacterial efficacy. As a broad-spectrum agent, it is formulated to be effective against a wide variety of microbial pathogens, encompassing both Gram-negative and Gram-positive bacteria, and is commonly used when treating typical bacterial infections.


Composition and Available Forms

The foundation of the Olfi preparation is the compound Ofloxacin, which functions as the sole primary active ingredient responsible for its antimicrobial effects. This medication is available in multiple dosage forms to facilitate different routes of administration. For systemic administration (acting throughout the body), it is typically formulated as an oral tablet using solid pharmaceutical excipients. It is also prepared in topical forms, such as ophthalmic solutions and otic solutions, which are aqueous-based preparations intended for focused, localized application. Ofloxacin is established as a significant medicine for fighting infections globally.


General Purpose: How Olfi Fights Infection

The general purpose of Olfi is to achieve the clearance of bacterial pathogens that cause illness within the body. Its mechanism of effect is profoundly bactericidal, meaning it actively works to kill the bacteria rather than merely inhibiting their growth. This action involves interfering with the bacteria's fundamental machinery that handles DNA replication and repair. This distinct mode of action ensures the definitive elimination of the microbial cause, thereby resolving the underlying bacterial infection.

Regulatory References

  1. Ofloxacin - StatPearls - NCBI Bookshelf
  2. WHO Model Lists of Essential Medicines
  3. Ofloxacin - eEML

What side effects are possible with Olfi?

Possible Side Effects and Safety Information

The safety profile of Olfi, whose active ingredient is Ofloxacin, is characterized by adverse reactions documented across multiple body systems, consistent with its classification as a fluoroquinolone antibiotic. Regulatory authorities define these reactions by frequency and the system-organ class affected, establishing the official risk characteristics.

Frequency and System-Organ Classification

Adverse reactions that are Commonly documented in regulatory labels involve the Gastrointestinal System (e.g., nausea) and the Nervous System (e.g., headache, dizziness, and insomnia). Effects are also grouped under Musculoskeletal, Psychiatric, Dermatological, and Cardiovascular systems.

Documented Serious Safety Risks

Official prescribing information highlights specific serious adverse reactions that are potentially disabling and may be permanent. These include effects on the Musculoskeletal and Nervous Systems, such as tendinitis, tendon rupture, and peripheral neuropathy (tingling or numbness). Serious Psychiatric reactions, including psychotic events and, rarely, suicidal thoughts, are also documented.

Furthermore, the medicine is associated with risks to the Cardiovascular System, including QT interval prolongation and an increased risk of aortic aneurysm and dissection, particularly noted in older adults. Severe, rare occurrences affecting the blood (pancytopenia) and liver (hepatic failure) are also listed in official documents.

Time-Related and Population-Specific Safety

Certain serious effects, such as tendinopathy, may manifest rapidly, sometimes within the first 48 hours of starting treatment, or may be delayed, occurring up to several months after discontinuing the medicine. Safety documents identify specific patient populations with heightened risk. The risk of tendon rupture is increased in older adults (over 60 years) and in patients concurrently receiving corticosteroids. The medicine is generally contraindicated in individuals with a history of hypersensitivity to fluoroquinolones or those with a central nervous system disorder that lowers the seizure threshold.

Overdose and Emergency Response

Acute overdosage with Olfi (Ofloxacin) requires immediate medical attention and is managed with supportive care, as no specific antidote is known. Officially documented overdose manifestations primarily involve the Central Nervous System (CNS), which may include confusion, drowsiness, dizziness, slurred speech, nausea, and vomiting. While less common, the risk of severe or life-threatening outcomes is documented, including the development of seizures, severe hypoglycemia (low blood sugar), and serious cardiac dysrhythmias such as QT interval prolongation and Torsade de Pointes.

The official regulatory guidance mandates seeking immediate medical help if signs of severe toxicity—such as loss of consciousness or seizures—occur. It is also necessary to contact a healthcare professional immediately for signs of tendon pain or swelling. For acute oral overdose, measures like gastric emptying and administration of activated charcoal may be used to limit absorption. Management procedures require close observation, specifically ECG monitoring, due to the potential for cardiac effects. The drug should be discontinued immediately upon suspicion of overdose or serious adverse reaction. Elderly patients and those with impaired kidney function may be at increased risk due to slower drug clearance and accumulation.

Therapeutic Uses of Olfi

What Olfi Treats: Main Uses and Benefits

Olfi is applied across domains where additional symptomatic support is needed in situations where short-term assistance is appropriate. The medicine is commonly used across conditions presenting with acute episodes where it may assist with managing symptoms. These conditions often include those characterized by recurrent or episodic manifestations, such as schizophrenia and episodes of mania or managing symptoms during phases of bipolar disorder.


Supporting Comfort and Stability

This use is applicable within clinical settings that involve acute or unstable symptom patterns, such as when symptoms appear suddenly or intensify, creating noticeable functional strain. Olfi provides support that helps ease the overall burden of symptoms, which may assist patients in coping more steadily with difficult episodes.

“This medication is relevant when symptoms become momentarily overwhelming, and may support maintaining a sense of stability.”

Olfi offers short-term symptomatic assistance, contributing to comfort during periods of heightened symptoms, and supports patients during episodes of discomfort that interfere with routine activities.

Quick Fact: Relevant for Disruptive Symptom Manifestations

Eligibility and Restrictions for Use

Eligibility for Olfi (Olanzapine) Use

The eligibility for Olfi is determined by official regulatory guidelines, defining approved populations, those for whom use is restricted, and those who are absolutely prohibited from taking the medicine.

Absolute Contraindications

Olfi is contraindicated (must not be used) in two primary groups. The most critical exclusion is for elderly patients with dementia-related psychosis, as official regulatory warnings state use in this population is associated with an increased risk of death. Additionally, patients with a documented hypersensitivity or allergy to olanzapine or any component of its formulation are strictly prohibited from use.

Age-Related Eligibility

Age Group Regulatory Status
Adults (18+) Approved for use under labeled conditions.
Adolescents (13–17) Approved for specific indications.
Children (<13) Safety and effectiveness have not been established.

Conditional and Restricted Use

Use is considered restricted or requires specific caution in several populations. For older adults (65+), a lower starting dose should be considered, though the prohibition for dementia-related psychosis still applies. Use during pregnancy requires a careful assessment of risks, and use during lactation is generally not recommended by the manufacturer. Furthermore, patients with hepatic impairment (liver dysfunction) should be considered for a lower initial dose, and use requires caution in those with a history of seizures or cardiovascular disease.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Olfi (Ofloxacin) is defined by established pharmacokinetic and pharmacodynamic relationships with specific substance categories as documented in regulatory labeling. The co-administration of certain products requires mandatory separation or caution due to the risk of altering Ofloxacin's systemic exposure or potentiating adverse effects.

Pharmacokinetic and Timing Constraints

The systemic exposure of Ofloxacin is significantly reduced when co-administered with substances containing divalent or trivalent cations. This chelation-based interference is explicitly documented for iron salts, magnesium- or aluminium-containing antacids, zinc supplements, and Sucralfate. To prevent a significant reduction in Ofloxacin absorption, mandatory timing rules require that these products must not be taken within two hours before or two hours after Ofloxacin tablet administration.

Pharmacodynamic Interaction Risks

Ofloxacin may create additive systemic risks when used concurrently with certain medications. Official documentation advises caution regarding co-administration with drugs known to prolong the QTc interval (such as Class IA and III antiarrhythmics), due to the potential for potentiating cardiac rhythm changes. Additionally, concurrent use with nonsteroidal anti-inflammatory drugs (NSAIDs) or Theophylline carries a pharmacodynamic risk of lowering the cerebral seizure threshold. Furthermore, Ofloxacin interacts with Vitamin K antagonists (e.g., Warfarin), which may lead to increases in coagulation parameters and bleeding risk, and may increase the risk of hypoglycemia when combined with oral hypoglycemic agents or insulin.

Mechanism of Action

Targeted Inhibition of Bacterial DNA Management

Ofloxacin initiates its action by selectively targeting two critical bacterial enzymes, DNA Gyrase (Topoisomerase II) and Topoisomerase IV, which are indispensable for bacterial DNA replication and transcription. The drug functions as an inhibitor, trapping these enzymes while they are bound to the DNA, ensuring the molecular cascade moves toward cellular damage. This engagement leads to the swift interruption of core genetic processes within the bacterial cell.


Induction of a Lethal Bactericidal Cascade

The molecular interference with the target enzymes triggers a bactericidal cascade characterized by the rapid accumulation of catastrophic double-strand DNA breaks. This extensive, irreversible genomic damage forces the bacterial cell into a state of physiological collapse and death. The overall physiological consequence of this mechanism is the reduction in the viable bacterial population, leading to the disruption of the microbial disturbance in the affected biological system.


Functional Constraints and Resistance Mechanisms

The functional capacity of the mechanism is biologically constrained by the pathogen's ability to evolve defense strategies. This involves mutations that structurally alter the target enzymes to reduce drug binding affinity, and specialized efflux pumps that actively expel the drug. When these defense mechanisms are engaged, Ofloxacin's intracellular concentration or binding affinity is insufficient to complete the lethal DNA damage cascade.

Dosage and Administration Information

How to Use Olfi: Official Administration Guidelines

Olfi (olanzapine) administration is defined by its route, form, and prescribed daily dosage. The medicine is available as oral tablets or orally disintegrating tablets (ODT) for daily use, and as a powder for short-acting intramuscular (IM) injection for time-limited acute management. An extended-release IM suspension is also available for long-term maintenance.

Dosing and Administration Practices

The standard oral daily dosage range is typically 5 mg to 20 mg, administered once daily. For many indications, the initial starting dose is 10 mg/day. Oral Olfi may be taken with or without food as absorption is not affected by meals.

Administration Type Dosing Schedule Special Condition
Oral Tablets Once daily (QD). Dosage increases should occur at intervals of not less than 24 hours. The ODT form should be allowed to disintegrate on the tongue and then swallowed with or without liquid.
IM Injection (Short-Acting) Initial dose is typically 10 mg. Up to three injections (max 30 mg) may be given in a 24-hour period, with a minimum interval of 2 hours between the first two doses. This route is intended for short-term use only, up to three consecutive days.

Population-Specific Instructions

Official prescribing information recommends that a lower starting dose (5 mg) should be considered for certain individuals, including older adults (65 years and older) and patients with renal or hepatic impairment.

Recent Clinical Evidence

Research evidence / Overview of Studies for Olfi (Ofloxacin)


Evidence for Use in Systemic Infections (Oral Tablet)

This section summarizes the types of high-quality clinical trials that have been conducted for Olfi tablets in examining internal bacterial infections, specifically those affecting the respiratory and urinary tracts. The research focuses on short treatment periods and the study of microbiological outcomes.

Studies for Respiratory Tract Infections (Pneumonia and Bronchitis)

Research explored the use of Olfi in adults experiencing acute bacterial exacerbations of chronic bronchitis and community-acquired pneumonia. These trials were often Randomized Controlled Trials (RCTs). The studies primarily monitored short-term outcomes related to the infection, such as clinical resolution rates and the microbiological eradication rates reported for the identified bacterial pathogens. The findings from these trials describe patterns of microbiological and clinical outcomes observed in the studied adult populations following the completion of the short, defined treatment period.

Studies for Urinary Tract Infections (UTIs) and Prostatitis

Controlled studies were evaluated in adults to examine the use of Olfi for both uncomplicated urinary tract infections (UTIs) and more complicated UTIs. For uncomplicated cases, short-course trials monitored the rates of bacterial clearance and the resolution of common symptoms. Findings indicate that short regimens were associated with measured rates of both clinical and microbiological outcomes in the immediate post-treatment period. Evidence is more heterogeneous for complicated infections, and long-term follow-up to assess sustained absence of infection, especially in chronic prostatitis, is not fully established across all studies.


Evidence for Localized Topical Use (Ophthalmic and Otic Solutions)

Studies for Superficial Eye Infections

Topical ophthalmic solutions were evaluated in randomized, controlled clinical trials for bacterial conjunctivitis or corneal ulcers. The outcomes measured were physical signs, such as the complete re-epithelialization of the corneal surface and the microbiological eradication of the bacteria from eye cultures. Findings describe physical outcomes and microbial clearance rates observed within the short, prescribed treatment duration. Data for the use of the topical solution in very young infants (neonates) remain insufficient.

Studies for Ear Infections

Controlled clinical trials have explored the use of the otic solution for conditions like Otitis Externa. The trials described the rates of clinical outcomes observed in the studied populations. The evidence for the otic solution is specific to the local delivery and does not necessarily apply to the oral tablet form.


What is Still Uncertain in the Research Landscape

The current research landscape contains several areas where more information is needed. Evidence quality varies across studies, and comparative evidence is lacking in some areas. A primary area of uncertainty, recognized by regulatory bodies, relates to the increasing prevalence of antimicrobial resistance, which may affect the measured outcomes over time. Furthermore, the evidence generally focuses on monitoring short-term clinical outcomes over the defined treatment course, meaning information regarding the durability of the response and long-term recurrence rates is limited.

Key Studies & References

  1. Ofloxacin Ophthalmic Solution 0.3% (Ocuflox®) Monograph (Referencing Conjunctivitis Trials)

Frequently Asked Questions (FAQ)

Common questions about Olfi (FAQ)

Q: How quickly does Olfi typically start to work after I begin taking it?

A: Clinical studies often describe that patients may notice some initial improvement in their symptoms within the first week of starting Olfi. However, the medicine’s concentration in the blood, known as the steady state, often takes a few months of continuous daily dosing to fully stabilize. This may influence the timeframe over which the medicine's full effect is assessed by healthcare professionals.

Q: If I miss a day of taking Olfi, what is generally described as the next step?

A: Official patient guidance indicates that if a dose is remembered, it may be taken as soon as it is remembered. If it is already almost time for the next scheduled dose, it is generally indicated to skip the missed dose and continue with the regular schedule. The guidance specifies that two doses should not be taken at the same time.

Q: What is the difference between Olfi and other medicines in the same class?

A: While all medicines in this class work in similar ways, research has described certain differences when comparing Olfi to others. Studies indicate that some differences may exist in outcomes such as medication adherence—meaning patients may stay on Olfi longer—or in its reported effects on certain aspects of a patient’s health, such as their overall insight into their condition.

Q: I heard Olfi can cause weight changes; is that a commonly discussed side effect?

A: Yes, official regulatory documents list weight gain as a commonly reported adverse reaction that may occur in both adults and adolescents using the medicine. Because of this, official warnings state that patient weight should be monitored regularly throughout treatment. This is part of the established safety information for Olfi.

Q: Does taking Olfi affect the ability to drive or operate machinery?

A: Official information advises that Olfi has the potential to affect a person’s judgment, thinking, and motor skills, particularly when treatment first begins. Official patient information notes that caution is warranted when engaging in activities such as driving or operating machinery, particularly before understanding the medicine’s potential effects. This is a common precaution for medicines that act on the central nervous system.

Q: Are there any specific vitamins or supplements that should not be taken with Olfi?

A: The official interaction profile mainly details constraints with other prescription drugs. However, official guidance recommends caution when combining Olfi with other medicines or supplements that cause drowsiness. Supplements containing mineral ions like iron or zinc must be taken hours apart from Olfi, as these minerals can significantly reduce the amount of Olfi the body absorbs, a separation that is specifically documented in regulatory labeling.

Q: Are there known interactions between Olfi and common over-the-counter pain relievers?

A: Official documents describe the need for caution when Olfi is used at the same time as medicines that interfere with blood clotting. This includes certain nonsteroidal anti-inflammatory drugs (NSAIDs). Co-administration with these drugs may potentiate the risk of bleeding.

Q: Does the time of day I take Olfi matter according to official information?

A: The medicine is typically prescribed to be taken once a day. While official prescribing information does not mandate a specific time (e.g., morning versus evening), regulatory documents indicate that consistent daily dosing is key to maintaining a steady concentration of the medicine in the bloodstream.

Q: Are there any specific lifestyle changes that are often recommended while taking Olfi?

A: Official patient counseling guides note that lifestyle factors should be monitored. Official guidance notes that the use of alcohol is associated with an increased risk of drowsiness when combined with Olfi. Official guidance includes caution regarding vigorous exercise or exposure to extreme heat, as the medicine may affect the body’s ability to regulate its temperature.

Q: Can Olfi affect the results of certain medical lab tests?

A: Yes, regulatory labeling notes that the use of Olfi is associated with certain metabolic changes that require laboratory monitoring. These changes include effects on fasting blood glucose levels and blood lipid (cholesterol and triglyceride) levels, which are routinely checked through blood tests.

Q: Are there differences in how Olfi affects men versus women?

A: Studies examining the metabolism of Olfi have indicated that women may show higher concentrations of the medicine in their blood plasma compared to men, even when taking the same dosage. This difference is considered when determining the appropriate dose and may affect how the medicine is tolerated.

Q: Can Olfi be split, crushed, or chewed?

A: Standard oral tablets are generally designed to be swallowed whole. However, compounding guidelines mention that if a patient cannot swallow pills, the standard tablet form may be crushed and mixed with a small amount of soft food. The orally disintegrating tablet (ODT) form, however, is specifically designed to dissolve on the tongue without being crushed or chewed.

Q: Does Olfi have any known effect on fertility?

A: Official labeling contains dedicated sections that address the medicine's use in 'Females and Males of Reproductive Potential.' These sections provide information, which may include data from animal studies, regarding any potential for impairment of fertility that has been observed.

How should Olfi be stored and disposed of?

How to Store and Dispose of Olfi

Official labeling defines specific storage requirements necessary to maintain the stability of Olfi (Olanzapine).


Storage Requirements

  • Temperature and Environment: Store the medicine at controlled room temperature, typically 20 C to 25 C (68 F to 77 F), ensuring the temperature does not exceed 25 C. The product must be kept dry and protected from light and excess heat.
  • Packaging Rules: The medication must be kept in the original container, tightly closed. Orally Disintegrating Tablets (ODTs) must be kept in their sealed blister pack until use and used immediately after opening.
  • Child Safety: It is a mandatory requirement to keep Olfi out of the sight and reach of children.

Disposal Instructions

For unused or expired medicine, disposal should primarily be through a drug take-back program. If this is unavailable, the product must not be flushed. Instead, mix the medicine with an undesirable substance (such as dirt or cat litter) in a sealed container and dispose of it in the household trash. It is required to scratch out all personal information on the label before discarding the container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Olfi found in:

A-Z Index: